The EphA2 receptor tyrosine kinase is overexpressed in a variety of human cancers. We sought to characterize the role of EphA2 in pancreatic adenocarcinoma and, using RNA interference (RNAi) mediated by small interfering RNA (siRNA), we determined the effects of suppressing EphA2 expression in vitro and in vivo. EphA2 expression in PANC1, MIAPaCa2, BxPC3 and Capan2 cells was assessed by Northern and Western blot. We artificially overexpressed EphA2 by transient transfection and suppressed EphA2 expression using RNAi. Cellular invasiveness was quantified by modified Boyden chamber assay. Anoikis was induced by anchorage-independent polyHEMA culture and caspase 3 activity was quantified fluorometrically. Focal adhesion kinase (FAK) phosphorylation was assessed by immunoprecipitation. EphA2 siRNA treatment was assessed in a nude mouse xenograft model. Pancreatic adenocarcinoma cells differentially express EphA2. Inherent and induced EphA2 overexpression is associated with increased cellular invasiveness and anoikis resistance. EphA2 siRNA suppresses EphA2 expression, cellular invasiveness, anoikis resistance and FAK phosphorylation in vitro and retards tumor growth and inhibits metastasis in vivo. EphA2 is both a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma.
Introduction
Pancreatic adenocarcinoma is currently the fourth leading cause of cancer-related death in the United States (Jemal et al., 2003) . Owing to the highly aggressive invasion, early metastasis and nonspecific symptoms characteristic of this malignancy, 90% of patients are diagnosed with surgically unresectable disease (Farrell et al., 1997) . Current chemotherapy regimes offer only marginal survival benefit, and alternative therapeutic strategies are urgently required.
Anticancer drug discovery has shifted from empiric random screening to a more rational and mechanistic, target-based approach, reflecting our expanding knowledge of cancer molecular pathogenesis (Balis, 2002) . RNA interference, mediated by small interfering RNA (siRNA), is a highly specific technique for suppressing individual gene expression (Elbashir et al., 2001) . We sought to determine whether siRNA-based targetspecific therapy would be a successful strategy for the treatment of pancreatic adenocarcinoma.
Eph kinases constitute the largest group of transmembrane receptor tyrosine kinases (RTKs) (Himanen and Nikolov, 2003) . Class A Eph receptors interact promiscuously with ligands of the ephrin A family, a group of glycosylphosphatidylinositol (GPI)-linked membrane proteins (Wilkinson, 2000) . Eph family RTKs and their ligands initially attracted interest as modulators of embryonic patterning and neuronal targeting (Holder and Klein, 1999) . In developing embryonic tissues, Eph and ephrin expression occurs in reciprocal embryonic compartments, with ligand-receptor interaction taking place at tissue boundaries Gale et al., 1996) . These interactions are postulated to prevent aberrant cellular migration across embryonic boundaries, thus maintaining normal tissue organization. In malignancy, characterized by deranged tissue organization, differential expression and functional alterations of Eph kinases have been reported to be prevalent (Kinch and Carles-Kinch, 2003; WalkerDaniels et al., 2003) .
EphA2, originally named epithelial cell kinase (Eck), is normally expressed at low levels in adult epithelial tissues (Lindberg and Hunter, 1990) . EphA2 is also a powerful oncoprotein, sufficient to confer malignant potential on nontransformed epithelial cells (Zelinski et al., 2001) . Overexpression of EphA2 is consistently associated with disease progression and highly malignant cellular phenotypes, including metastasis (WalkerDaniels et al., 1999; Zelinski et al., 2001) . Binding of EphA2 to its ligand ephrin A1, which has been shown to induce proteosomal degradation of membrane-bound EphA2 (Walker-Daniels et al., 2002) , inhibits breast and prostate adenocarcinoma cellular proliferation and migration (Zantek et al., 1999; Miao et al., 2000; Zelinski et al., 2001) . Targeting of EphA2 with antibodies and antisense oligonucleotides has also been reported to reverse breast adenocarcinoma cell growth and migration (Carles- . These observations make EphA2 of interest, both as a potential oncoprotein and as a target for anticancer therapy.
Here, we show that EphA2 is differentially expressed by pancreatic adenocarcinoma cells. The effects of EphA2 overexpression on in vitro malignant cellular behavior are assessed. Using EphA2-specfic siRNA to inhibit EphA2 expression at the post-transcriptional level, we demonstrate the effects of EphA2 gene silencing on pancreatic adenocarcinoma cellular behavior in vitro. EphA2-specific siRNA is evaluated in vivo using a nude mouse xenograft model. This study is the first to characterize EphA2 expression and its contribution to malignant cellular behavior in pancreatic adenocarcinoma. EphA2 is identified not only as an important determinant of malignant cellular behavior but also as a rational therapeutic target in pancreatic adenocarcinoma.
Results
EphA2 is a determinant of pancreatic adenocarcinoma malignant cellular behavior PANC1, MIAPaCa2, BxPC3 and Capan2 cells showed differential expression of EphA2 at both transcript and protein levels (Figures 1 and 2 ). EphA2 was relatively overexpressed in PANC1 and MIAPaCa2, which are poorly differentiated cell lines with higher in vivo metastatic ability (50 and 67%, respectively, of nude mice orthotopically implanted with these cells had developed liver metastases by 6 weeks following implantation). Lowest levels of EphA2 were expressed by Capan2, a cell line with relatively poor in vivo metastatic ability (no metastases had developed six weeks following orthotopic implantation) (Figures 1 and  2 ). As Capan2 expresses low levels of EphA2, it was chosen to further explore the role of EphA2 in malignant cellular behavior. EphA2 overexpression was induced in Capan2 cells by transient transfection and confirmed by Western blot analysis. Invasiveness was assessed by modified Boyden chamber assay. Cells (2 Â 10 4 ) were added to the inserts of growth factordepleted Matrigel-coated 8-mm pore invasion chambers and the degree of invasion toward an FBS chemoattractant determined after 24-h culture. Artificial overexpression of EphA2 increased Capan2 cellular invasiveness in vitro (Figure 3b ).
Anoikis is a subset of apoptosis induced by inadequate or inappropriate cell-substrate contact, and is thought to maintain tissue order by preventing ectopic cellular proliferation (Meredith Jr et al., 1993; Frisch and Francis, 1994) . Resistance to anoikis correlates with cellular propensity for tumorigenesis and metastasis in a number of malignancies (Yawata et al., 1998; Streuli and Gilmore, 1999; Shanmugathasan and Jothy, 2000) . We therefore assessed the effect of EphA2 overexpression on resistance to anoikis. PolyHEMA culture (Folkman and Moscona, 1978) , a well-established means of depriving cells of contact with substratum (Raz and Ben Ze'ev, 1983; Kim et al., 1999) , was used to induce anoikis. EphA2 overexpression increased the resistance of Capan2 to anoikis induced by polyHEMA culture (Figure 3c ). Induced overexpression of EphA2 had no significant effect on proliferation in monolayer culture, consistent with observations reported by Zelinski et al. (2001) .
Suppression of EphA2 expression by siRNA
To assess whether EphA2 could serve as a therapeutic target, we designed sense and antisense siRNA oligonucleotides targeting the coding region of EphA2. BLAST search confirmed that the siRNAs did not share sequence homology with that in any other known human gene. The ability of EphA2 siRNA to suppress EphA2 expression in pancreatic adenocarcinoma cells was initially assessed in vitro. The four pancreatic adenocarcinoma cell lines were treated with EphA2 siRNA or control siRNA. At 48 h post-transfection, cells were harvested and EphA2 expression was analysed by Northern and Western blotting. EphA2 siRNA treatment suppressed EphA2 protein expression by between 78 and 88% (Po0.05, Figure 1) . The results obtained using a polyclonal EphA2 antibody were confirmed using a monoclonal (clone D7) anti-EphA2 antibody (data not shown). A corresponding suppression of EphA2 transcript was observed (Figure 2) . Suppression of EphA2 protein expression occurred within 24 h of transfection and persisted for 5 days in culture. Control single-base mismatch siRNA had no effect on EphA2 expression. To confirm that EphA2 siRNA was specific for EphA2, we assessed expression of the Eph A family member EphA1 following administration of EphA2 siRNA or control siRNA. EphA1 protein expression was unaffected by either siRNA. In addition, actin expression was unaffected by either siRNA. These observations indicate that nonspecific suppression of protein expression is not induced following transfection of these siRNAs.
EphA2 siRNA suppresses cellular invasiveness and anoikis resistance but does not affect cellular proliferation in monolayer culture Next, we assessed the effect of EphA2 siRNA treatment on cellular invasiveness. At 48 h post-transfection, cellular invasiveness was quantified by Modified Boyden chamber assay over 24 h. EphA2 siRNA significantly reduced the invasiveness of all four pancreatic adenocarcinoma cell lines (Figure 4 ). Control siRNA had no effect on cellular invasiveness. Anoikis was induced by culture under anchorageindependent conditions using polyHEMA-coated wells. Treatment with EphA2 siRNA promoted anoikis in all four cell lines. Control siRNA had no effect on the anoikis fraction ( Figure 5a ). Caspase 3 activity of cells in polyHEMA culture was also increased by EphA2 siRNA treatment (Figure 5b ). Caspase 3 activity in monolayer culture was unaffected by either siRNA treatment. Treatment with neither EphA2 siRNA nor control siRNA significantly affected cellular proliferation or apoptosis in monolayer culture.
EphA2 siRNA decreases focal adhesion kinase (FAK) phosphorylation
Overexpression of FAK is associated with increased invasiveness and anoikis resistance in a variety of tumor cells (Owens et al., 1995; Kornberg, 1998; Hauck et al., 2002; Schneider et al., 2002; Hsia et al., 2003; Miyazaki et al., 2003) . FAK is functionally important in both EphA2 and integrin signaling (Miao et al., 2000) , and ephrin A1-mediated changes in cytoskeletal architecture require FAK (Carter et al., 2002) . We therefore assessed the effect of EphA2 siRNA on FAK phosphorylation, as its phosphorylation status is a reflection of FAK kinase activity (Guan and Shalloway, 1992; Calalb et al., 1995) . At 48 h post-siRNA transfection, FAK was immunoprecipitated from MIAPaCa2 cells, which inherently express relatively high levels of FAK. EphA2 siRNA significantly suppressed FAK phosphorylation. Control siRNA had no effect on FAK phosphorylation ( Figure 6 ).
EphA2 siRNA treatment inhibits tumor growth and metastasis in vivo
Given these findings in vitro, we tested EphA2 siRNA using an in vivo nude mouse xenograft model. Male athymic nude mice were implanted subcutaneously with 10 6 MIAPaCa2 pancreatic adenocarcinoma cells. MIAPaCa2 cells were chosen as, in addition relatively overexpressing EphA2, they are highly tumorigenic and fast-growing in the athymic mouse (Weckbecker et al., 1997) . Once tumors reached 50 mm 3 (10 days-post implantation), treatment was initiated with EphA2 siRNA (150 mg/kg in 200 ml phosphate-buffered saline (PBS), n ¼ 10), control siRNA (150 mg/kg in 200 ml PBS, n ¼ 10) or PBS (200 ml, n ¼ 10), administered by tail-vein injection twice weekly for 6 weeks. There was no evidence of any adverse reaction to siRNA treatment. Tumor growth was significantly retarded by EphA2 siRNA treatment compared to the control siRNA and PBS-treated groups. The difference in tumor volume was statistically different by the third week of treatment and at every time point subsequently (Figure 7a ). After 6 weeks of PBS and control siRNA treatment, the mean tumor volumes were 180 and 170 mm 3 , respectively. In the EphA2 siRNA treated group, the mean tumor volume was 40 mm 3 (Po0.05 between EphA2 siRNA group and both control siRNA and PBS-treated groups (P40.05 between control-siRNA and PBS-treated groups). The tumor growth inhibition (TGI), derived from mean tumor masses at week 6 as described, was 70% in the EphA2 siRNA-treated group compared to the control siRNA-treated group (Po0.05). Suppression of tumor EphA2 expression by systemic EphA2 siRNA was confirmed by Western blot analysis of tumor homogenates (Figure 7b ). The EphA2 expression in control siRNA and PBS-treated tumors was not significantly different. Actin expression was not affected by treatment with EphA2 or control siRNA. The mean tumor apoptotic fraction (Figure 7c ) and tumor homogenate caspase 3 activity ( Figure 7d) were increased in the EphA2 siRNA-treated group compared to the control siRNA-treated group. Liver metastases were detected in eight of the 10 mice treated with PBS and seven of those treated with control siRNA. In the EphA2 siRNA-treated group, only one mouse developed a liver metastasis (Table 1) .
Discussion
Overexpression of EphA2 is implicated in the development and progression of a number of human malignancies, including melanoma and breast, prostate and colon carcinoma (Easty et al., 1995; Rosenberg et al., 1997; Walker-Daniels et al., 1999; Zelinski et al., 2001) . In this study, we have demonstrated that EphA2 is Figure 7 EphA2 siRNA suppresses EphA2 expression and inhibits tumor growth in a nude mouse xenograft model. Nude mice were injected subcutaneously with 10 6 MIAPaCa2 cells. Once tumors had reached 50 mm 3 , treatment was commenced twice weekly with EphA2 siRNA (150 mg/kg in 200 ml, n ¼ 10), control single-base mismatch siRNA (150 mg/kg in 200 ml, n ¼ 10) or PBS (200 ml, n ¼ 10). (a) Tumor volume was calculated weekly. After 6 weeks, necropsy was performed. Tumor homogenates were assayed for EphA2 expression by Western blot (b). In total, 5 mM tumor sections were TUNEL stained for apoptotic cells (c). Tumor homogenate caspase 3 activity was determined by fluorometric assay (d). EphA2 siRNA, but neither control siRNA nor PBS, inhibited tumoral EphA2 expression. Actin expression was unaffected by siRNA treatment. Tumor growth was retarded (TGI 70%) in the EphA2 siRNAtreated group compared to the control siRNA-treated group. The apoptotic fraction was significantly increased and caspase 3 activity was higher in the EphA2 siRNA treated group, compared to the control siRNA-treated group. Values are means7s.d. *Po0.05 The mechanisms by which EphA2 overexpression imparts aggressive cellular phenotypes are poorly understood. Overexpression of EphA2 has recently been reported to decrease the dependence of breast cancer cells on estrogen for proliferation and to reduce the sensitivity of these cells to tamoxifen (Lu et al., 2003) . The effects of EphA2 overexpression and gene silencing were not apparent in monolayer culture, but were observed to affect cellular invasiveness and survival in anchorage-independent polyHEMA culture. These observations are consistent with work by Zelinski et al. (2001) , who observed no phenotypic effects of EphA2 overexpression on cells grown in monolayer culture. EphA2 overexpression was reported to assume greater importance in a three-dimensional culture model.
Interactions between Eph kinases and ephrins maintain order within developing tissues. In normal adult tissues, EphA2 is expressed at low levels and binds stably to its ligand, ephrin A1 (Zantek et al., 1999) . Conversely, in malignant disease, which is characterized by abnormal tissue organization, EphA2 overexpression is common and normal ephrin A1 binding is reduced (Bartley et al., 1994; Zantek et al., 1999) . EphA2 is usually degraded following ligand binding (Carles- Walker-Daniels et al., 2002) but, when EphA2 is overexpressed, impaired ligand binding is thought to stabilize EphA2, leading to a further impairment of ligand binding and EphA2 accumulation (Kinch and Carles-Kinch, 2003) . In the presence of EphA2 overexpression, suppression of tumor growth, decreased cellular invasiveness and inhibition of Ras/ MAPK cascade activity, all of which are normally induced by ephrin A1 binding, no longer occur (Miao et al., 2001; Zelinski et al., 2001) . A putative 'vicious cycle' would be perpetuated by stimuli that increase EphA2 expression such as abnormal Ras signaling (Miao et al., 2001 ) and p53 mutation (Dohn et al., 2001) , which are common to pancreatic adenocarcinoma.
The mechanisms by which suppression of EphA2 expression would inhibit invasiveness and anoikis resistance are not fully established, but our observation that EphA2 siRNA decreases FAK phosphorylation is interesting for a number of reasons. FAK is required for ephrin A1-mediated signaling (Carter et al., 2002) and EphA2 constitutively associates with FAK in resting cells. EphA2 is reported to regulate membrane localization of FAK in an activation state-dependent manner (Miao et al., 2000) , and Ephrin-A1 stimulation of EphA2 activity induces dissociation of FAK from EphA2, dephosphorylation of FAK and paxillin, resulting in actin cytoskeletal changes. Suppression of EphA2 expression would reduce levels of EphA2 available for association with FAK, and may explain the FAK dephosphorylation we observed following suppression of EphA2 expression. Reduced FAK phosphorylation correlates with decreased FAK kinase activity, which is likely to contribute to the impaired invasiveness and anoikis resistance induced by EphA2 siRNA treatment (Frisch et al., 1996; Kornberg, 1998) .
Using cultured pancreatic adenocarcinoma cells, we confirmed the ability of siRNA to suppress EphA2 expression specifically. We observed in vivo suppression of EphA2 gene expression by systemically administered siRNA. Intravenously administered siRNA, in a dose similar to that used in our study, has recently been reported to suppress gene expression in a murine tumor model (Filleur et al., 2003) . The reasons for the ability of systemically administered siRNA to suppress tumoral gene expression are not yet clear, but the inherently high permeability of tumor neovasculature (Dvorak, 1990) may be contributory. However, the potency of siRNA is still limited by intratumoral bioavailability and the transient nature of gene silencing. Plasmid and viral vectors producing siRNA using the polymerase III promoter (Brummelkamp et al., 2002; Wilda et al., 2002) may offer more efficient siRNA delivery and induce stable gene silencing. Even though EphA2 expression was not completely inhibited by siRNA treatment, the effects on malignant cellular behavior and tumor progression were marked, emphasizing the importance of EphA2 expression as a determinant of cellular invasiveness and survival under anchorageindependent conditions. We observed no adverse effects in the mice treated with siRNA, and EphA2-specific therapy would be expected to have little toxicity in normal adult human tissues where EphA2 expression is low.
Anticancer drug development is undergoing a paradigm shift from empirical and serendipitous discovery to targeted drug design (Balis, 2002) . Although targetspecific treatments offer the promise of fewer systemic side effects, strategies such as antisense oligonucleotide treatment have been hampered by exacting target sequence requirements, low potency and inadequate specificity (Braasch and Corey, 2002) . Treatment with siRNA is reported to be quantitatively more efficient and to have greater in vivo potency, compared to antisense oligonucleotides (Bertrand et al., 2002) . Double-stranded siRNA is more resistant to nuclease degradation than antisense oligonucleotides, an observation which may account for the observed therapeutic efficacy of systemically administered siRNA. While the effects of EphA2 siRNA on in vitro invasiveness, anoikis resistance and the results obtained in the nude mouse model should be regarded as correlative and extrapolated cautiously, siRNA is a promising addition to the experimental therapeutic armamentarium.
In summary, we present the first evidence that the EphA2 receptor is a determinant of pancreatic adenocarcinoma malignant behavior. Suppression of EphA2 expression impairs in vitro cellular invasiveness and anoikis resistance, without affecting proliferation or apoptosis in monolayer culture. In addition, treatment of tumor-bearing mice with siRNA directed against EphA2 results in impaired in vivo tumor progression. These data identify EphA2 not only as an important determinant of pancreatic adenocarcinoma malignant behavior but also as a promising therapeutic target.
Materials and methods

Cell lines
Poorly differentiated human pancreatic cancer cell lines PANC1and MIAPaCa2 and the well-differentiated lines BxPC3 and Capan2 were obtained from ATCC (Rockville, MD, USA) and maintained in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS) in a humidified (371C, 5% CO 2 ) incubator. All cell lines were subcultured before confluence and seeded at a density of 1 Â 10 4 cells/cm 2 . All cell lines are able to form tumors in nude mice (Miknyoczki et al., 1999) .
Transient transfection
EphA2 cDNA inserts were produced by PCR (primer 1: 5 0 -CACCATGGAGCTCCAGGCAGC-3 0 ; primer 2: 5 0 -TCA GATGGGGATCCCCACAGT-3 0 ). The PCR products were inserted into the pENTR TOPO vector, expanded in OneShot TOP10 cells and transferred to the pcDNA3.2-DEST expression vector in accordance with the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Transfection was performed using Lipofectamine 2000 Reagent (Invitrogen) in accordance with the manufacturer's protocol. Assays were performed 48 h post-transfection.
In vitro siRNA treatment 0 were synthesized and purified by Qiagen-Xeragon (Germantown, MD, USA). The target specificity of these sequences was confirmed by BLAST search (http://www.ncbi. nih.gov/BLAST). Homologous siRNAs were dissolved in buffer (100 mM potassium acetate, 30 nM HEPES-potassium hydroxide, 2 nM magnesium acetate, pH 7.4) to a final concentration of 20 mM, heated to 901C for 60 s and incubated at 371C for 60 min prior to use to disrupt any higher order aggregates formed during synthesis. Cells were plated into 35 mm six-well trays and allowed to adhere for 24 h. In all, 8 ml siPORT Amine transfection reagent (Ambion Inc., Austin, TX, USA) per well was added to serum-free medium for a final complexing volume of 200 ml, vortexed and incubated at room temperature for 15 min. The transfection reagent/siRNA complexes were added to the wells containing 800 ml medium with 10% FBS and incubated in normal cell culture conditions for 6 h, after which 1 ml DMEM containing 10% FBS was added. Assays were performed 48 h post-treatment.
Northern blot analysis
The total RNA samples were prepared using Trizol reagent (Gibco BRI, Rockville MD, USA), according to the manufacturer's instructions. In all, 20 mg total RNA, quantified by UV spectrophotometry, was electrophoresed through a denaturing gel (1.2% agarose, 2.2 M formaldehyde) and blotted onto a positively charged nylon membrane. After crosslinking with 120 mJ/cm 2 ultraviolet irradiation, the filter was prehybridized for 4 h at 421C in 5 Â SSPE, 5 Â Denhardt's solution, 0.1% SDS and 100 mg/ml denatured salmon sperm DNA. Oligonucleotide probes were synthesized by PCR using the primers (5 0 -GCCCGCAACATCCTCGTCAA-3 0 and 5 0 -GCAGCCGCACCCCAATCCTC-3 0 ) (Fujiwara et al., 2002) . The b-actin probe (5 0 -ATTTCCCGCTCGGCCGTGGTGGT GAAGCTGTAGC-3 0 ) was custom synthesized by SigmaGenosys (The Woodlands, TX, USA) and labeled with [a-32 P]ATP using the StripEZ kit (Ambion Inc, Austin, TX, USA). Hybridization was carried out with 50ng probe at 421C for 16 h. The filter was washed four times in 5 Â SSPE, 0.1% SDS for 10 min and exposed to XAR film (Eastman Kodak Co., Rochester, NY, USA). After detection, the filter was stripped and reprobed for b-actin. The signal was quantified using ImagePro Plus software version 4.0 (Media Cybernetic, Silver Spring, MD, USA) and normalized to that of b-actin. A minimum of three independent determinations was performed.
Western blot analysis and immunoprecipitation
Cells (2 Â 10 6 ) were harvested and rinsed twice with PBS, pH 7.4. Cell extracts were prepared with lysis buffer (20 mM Tris, pH 7.5, 0.1% Triton X, 0.5% deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin) and cleared by centrifugation at 12000 g, 41C. The total protein concentration was measured using the BCA assay kit (Sigma, St Louis, MO, USA) with bovine serum albumin as a standard, according to the manufacturer's instructions. Cell extracts containing 30 mg total protein were subjected to 10% SDS/PAGE, and the resolved proteins transferred electrophoretically to PVDF membranes (Invitrogen, Carlsbad, CA, USA). After blocking with PBS containing 0.2% casein for 1 h at room temperature, membranes were incubated with 5 mg/ml rabbit polyclonal anti-EphA2 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) in PBS containing 0.1% Tween 20 overnight at 41C. These findings were confirmed using an EphA2-specific mouse monoclonal antibody (clone D7, Sigma) at a concentration of 3 mg/ml. EphA1-specific antibody (Santa Cruz) was used at a concentration of 5 mg/ml). Chemoluminescent detection (Upstate, Lake Placid, NY, USA) was performed in accordance with the manufacturer's instructions. Equal protein loading was confirmed by stripping the membrane and reprobing with 3 mg/ml anti-actin monoclonal antibody (Lab Vision, Freemont, CA, USA). The EphA2 expression was quantified by densitometry and normalized to actin using ImagePro-Plus software.
Cell lysates from EphA2 and control siRNA-treated cells, containing 400 mg of total protein, were incubated with anti-FAK monoclonal antibody immobilized onto protein Gsepharose 4B beads (Upstate, Waltham, MA, USA) for 2 h at 41C with gentle rotation. Beads were washed extensively with lysing buffer, and immune complexes were eluted with 2 Â LDS sample buffer (Invitrogen), boiled and microcentrifuged. Proteins were resolved by probing with 3ı`g/ml antiphosphotyrosine (Santa Cruz, Santa Curz, MA, USA) and anti FAK antibody. A minimum of three determinations was performed.
Cellular proliferation assay
Cells (10 5 ) were seeded into wells of a six-well culture dish (Corning, Acton, MA, USA) in 2 ml of appropriate medium. After 48 h of incubation (371C, 5% CO 2 ), cells were harvested with trypsin-EDTA solution (Life Technologies, Gaithersburg, MD, USA) and counted using a hemocytometer (Hausser Scientific, Horsham, PA, USA) and trypan blue exclusion. Each experiment was repeated three times and the mean values were used for comparison.
Invasion assay
At 48 h following treatment with EphA2 siRNA or control siRNA, invasion was quantified using a modified Matrigel Boyden chamber assay. The BD BioCoat Matrigel invasion chamber (BD Bioscience, Bedford, MA, USA) was used according to the manufacturer's instructions. Pancreatic cancer cells (2.5 Â 10 4 ), in serum-free media, were seeded onto Matrigel-coated filters. In the lower chambers, 5% FBS was added as a chemoattractant. After 24 h incubation, the filters were stained with Diff-Quik TM kit (BD Biosciences), and the number of cells that had invaded through the filter was counted under magnification (randomly selected high-power fields). The counting was performed for three fields in each sample, and the mean values from three independent experiments were used.
Anoikis induction and detection
Anoikis was induced by PolyHEMA (Sigma, St Louis, MI, USA) culture. A solution of 120 mg/ml polyHEMA in 100% ethanol was made and diluted 1 : 10 in 95% ethanol 0.95 ml/ mm 2 of this solution was pipetted into 35-mm wells and left to dry for 48 h at room temperature. Prior to use, wells were washed twice with PBS and once with DMEM. Cells (1 Â 10 6 ) of each line, suspended in 2 ml DMEM with 10% FBS, were incubated in the PolyHEMA-coated wells for 16 h in a humidified (371C, 5% CO 2 ) incubator. Following induction of anoikis, cells were washed, resuspended in 0.5 ml of binding buffer and annexin V-FITC/propidium iodide labeling was performed in accordance with the manufacturer's protocol (BD Biosciences Pharmigen, San Diego, CA, USA). Analysis was performed by flow cytometry (FACScan, Becton Dickinson). The anoikis fraction (% cells undergoing anoikis: annexin V-FITC-positive, propidium iodide-negative) was calculated by scoring no less than 10 4 cells. The same method was used for detection of apoptosis (apoptotic fraction) of cells treated in standard culture. All observations were repeated in triplicate and the mean values reported.
Caspase assay
Lysates were assayed for caspase 3 activity using the BD ApoAlertt fluorometric Caspase Assay Plate (BD Biosciences Clontech, Palo Alto, CA, USA) in accordance with the manufacturer's instructions. Plates were read (excitation 360 nM; emission 480 nM) using a CytoFluor s 4000 (Applied Biosystems, Foster City, CA) multi-well fluorescence plate reader. A minimum of three determinations was performed for each sample.
Nude mouse xenograft model
Male athymic nu/nu mice 5 weeks of age, weighing 20-22 g and specific pathogen-free were obtained from Charles River Laboratories (Wilmington, MA, USA). Mice were housed in microisolator cages with autoclaved bedding in a specific pathogen-free facility with 12 h light-dark cycles. Water and food were supplied ad libitum. Animals were observed for signs of tumor growth, activity, feeding and pain in accordance with the guidelines of the Harvard Medical Area Standing Committee on Animals.
In an initial study of the inherent in vivo metastatic ability of each cell line, mice were implanted orthotopically with 10 6 cells of each pancreatic adenocarcinoma line and necropsy was performed 6 weeks later to allow assessment of in vivo liver metastasis. Mice were anesthetized with intraperitoneal ketamine (200 mg/kg) and xylazine (10 mg/kg). Mice were observed over 6 weeks and killed by overdose of ketamine (400 mg/kg) and xylazine (50 mg/kg). The liver of each animal was harvested, metastatic foci were counted under a dissecting microscope (Gorelik et al., 1991) and confirmed by hematoxylin and eosin staining.
To determine the effect of EphA2 gene silencing on tumor growth and metastasis, mice were subcutaneously implanted with 10 6 MIAPaCa2 cells. Tumor dimensions were measured weekly and the tumor volumes calculated using the formula: 1/ 2 Â a Â b 2 , where a and b represent the larger and smaller tumor diameters, respectively. After 6 weeks' treatment, necropsy was performed. Tumors were weighed and liver metastases were counted and confirmed histologically. TGI was calculated using the formula TGI (%) ¼ (1-M T / M C ) Â 100, where M T and M C are the mean tumor masses in the treatment group and control group, respectively (Sun et al., 2003) . TUNEL staining was performed on 5-mM sections of the excised tumors. The number of apoptotic cells was counted and expressed as a percentage of total cells (apoptotic fraction) in five random high-power fields. Tumor homogenates were assayed for EphA2 by Western blot and for caspase 3 activity as previously described.
Statistical analysis
The differences between groups were analysed using Student's t-test, multifactorial ANOVA of initial measurements and Mann-Whitney U-test, for nonparametric data, as appropriate, using Statistica 5.5. software (StatSoft, Inc., Tulsa, OK, USA). In cases where averages were normalized to controls, the standard deviations of each nominator and denominator were taken into account in calculating the final standard deviation. Po0.05 was considered statistically significant.
